在出血障碍中新出现的病原体的临床观点
Christopher A Ludlam1, William G Powderly, Samuel Bozzette
1University of Edinburgh, Edinburgh, UK. Christopher.Ludlam@ed.ac.uk
Lancet (London, England)
|January 24, 2006
概括
血衍生凝固因子缩剂 (CFC) 对已知的病毒是安全的. 然而,新出现的病原体和制造工艺存在持续的感染风险,推动开发更安全的重组替代品.
科学领域:
- 血液学 血液学 血液学
- 病毒学 病毒学
- 生物技术是生物技术.
背景情况:
- 血衍生的凝血因子缩剂 (CFC) 经过严格的查和病毒减少,确保了对许多已知的输血传播病毒 (如HBV,HCV,HIV和HTLV) 的安全.
- 尽管取得了进展,但新出现的病原体,特别是非脂质覆盖的病毒,具有抗不激活的血液传播阶段,对血衍生产品构成潜在的未来威胁.
研究的目的:
- 对已知和新出现的传染病原体进行血衍生CFC的安全性审查.
- 讨论动物传播和病毒进化对血产品安全构成的挑战.
- 突出重组凝血因子缩剂 (rCFC) 作为更安全的替代品的发展和益处.
主要方法:
- 审查当前的查和血捐献的病毒减少过程.
- 分析新兴病原体的特征及其对血衍生物产品的潜在影响.
- 对重组产品的安全概况和制造优势的评估.
主要成果:
- 由于先进的制造和查,目前的CFC被认为是免受广泛的病毒威胁的威胁.
- 新兴的传染病原体和固有的生物变异性对血衍生疗法的长期安全性提出了持续的挑战.
- 再组合凝血因子缩剂 (rCFC) 通过消除生产中人类血的需要和完全使用非人类衍生的试剂来提高安全性.
结论:
- 虽然血衍生CFC已经达到高安全标准,但由于传染风险不断变化,需要持续保持警.
- 重组技术在确保凝血因子治疗的安全性和可靠性方面取得了重大进展.
- 向重组产品的转变减轻了与人体血采购和病毒污染相关的风险,提高了患者的安全.
相关概念视频
02:45Blood Transfusion and Agglutination
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:24Tissue Transplantation
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:25Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...